AstraZeneca PLC said on Monday that it has signed a deal with Allergan PLC AGN, +0.05% worth up to $1.52 billion through its global biologics research and development unit.
The bio-pharmaceutical company said that under the deal, Allergan will have the global rights to an antibody for Crohn’s disease.
Allergan will pay upfront $250 million, but it may also make some payments to AstraZeneca worth up to $1.27 billion, depending on how good the sales of the antibody are, the company said.
By Olga Cotaga
Source: MarketWatch
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
